Pfizer has ended development of its experimental daily weight loss pill, danuglipron, after a trial patient showed signs of potential liver injury.

Although the patient’s liver enzymes quickly returned to normal after stopping the drug, Pfizer halted the program after reviewing all clinical data and regulatory feedback.

This marks another setback in Pfizer’s attempt to enter the booming GLP-1 weight loss drug market, currently led by Eli Lilly and Novo Nordisk, CNBC has reported.

Despite this, Pfizer continues to develop other obesity drugs, including an oral GIPR blocker and another once-daily GLP-1 pill in early trials.

Written by B.C. Begley